Skip to main navigation

Our Science
Investors & Media
Investor Relations
Who We Are
Contact
Patients & Caregivers

Press Releases

Year

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

January 15, 2025

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

January 14, 2025

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

January 13, 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2025

Terms of Use
Copyright Statement
Privacy Policy
Contact

© 2025 Verastem, Inc. All Rights Reserved.